Redeye comments on the Q2 report and expected upcoming news flow.
Redeye is impressed by the continued strong performance in the first quarter of fiscal year 2021/22.
The Q2 results were broadly in line with our expectations in terms of revenue, but below on EBITDA.
Redeye comments on the H1 report from Herantis Pharma.
Redeye sticks to its positive view following the Q2 report and recent project news flow.
Redeye comments on Enviro’s Q2 report which held no surprises.
ChromoGenics publicerade idag den 26 augusti sin delårsrapport för årets andra kvartal.
Euroafrica Digital Ventures AB (”Euroafrica” eller ”bolaget”) publicerade idag den 26 augusti 2021 s...
Genom att kombinera en organisk expansion via samarbeten och partnerskap, samt strategiska förvärv, ...
AVTECH reported a result very much in line with Redeye’s estimates.
Redeye comments on Alelion’s Q2 report, where sales grew 460% y-o-y, clearly illustrating the turnar...
Abelco publicerade den 26 augusti 2021 sin delårsrapport för andra kvartalet 2021.
There are no big surprises in Alzinova’s Q2’21 interim report.
Redeye comments on the Q2 report from Vicore. We provide a brief comment on the financials and highl...
Redeye maintains a positive view on LIDDS after today's Q2 report.
Redeye states that while semiconductor shortage affect automotive sales negatively, we maintain our ...
Q2 performance bodes well for FY guidance Revisions to reflect a change to calendar year Exciting ad...
Insplorions nettoomsättning Q2'21 var 0,5 mkr och EBITDA −3,5 mkr.
Omsättningen för Q2 uppgick till 2,8 mkr (2,8 mkr) motsvarande en organisk tillväxt om 1 %.
Intäkterna för Q2 var 36 mkr (31,5 mkr i Q2'20) motsvarande en tillväxt om 14 %.
Nettoomsättningen steg 38% y/y till 3,5 mkr (2,5), vilket var något under vår förväntan om 5,0 mkr.
Sales and profits in Q2 were lower than our estimates.
Redeye briefly comments on Cereno’s Q2 2021 report, which came without any surprises.
DistIT AB (publ) (”DistIT” eller ”Bolaget”) är historiskt ett distributionsbolag som nu är i början ...
Redeye provides a brief comment on Clavister's Q2 report.
FluoGuide has been demonstrating good progress with its clinical and preclinical programs, and FG001 appears to be exceeding expectations, w...
Footway Group – the online footwear and sports retailer – reported Q2 sales and earnings below our e...
While Q2 sales came in ahead of our estimates, adjusted EBITA was SEK 14m lower than expected, mainl...
